KEUMHEE BYEON: Open Payments
NPI 1194325431 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$375 in 11 payments from 7 companies in 2025. Trend: 2023 $1,167 · 2024 $285 · 2025 $375
Food & beverage: $375
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 1 | $103 |
| E.R. Squibb & Sons, L.L.C. | 2 | $80 |
| ABBVIE INC. | 3 | $68 |
| Neurocrine BioSciences, Inc. | 2 | $47 |
| Otsuka America Pharmaceutical, Inc. | 1 | $32 |
| Janssen Pharmaceuticals, Inc | 1 | $26 |
| Alkermes, Inc. | 1 | $20 |
Products named: UZEDY, COBENFY, VRAYLAR, INGREZZA, ABILIFY ASIMTUFII, INVEGA SUSTENNA, ARISTADA.
Industry payments across CA — which companies pay providers there.
